Pieris Pharmaceuticals Inc PIRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PIRS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $11.93
- Day Range
- $11.38–11.63
- 52-Week Range
- $10.89–80.80
- Bid/Ask
- $11.51 / $11.73
- Market Cap
- $14.24 Mil
- Volume/Avg
- 8,466 / 11,441
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.31
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 50
- Website
- https://www.pieris.com
Valuation
|
Metric
|
PIRS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.54 |
Price/Sales | 0.31 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PIRS
|
|---|---|
Quick Ratio | 2.72 |
Current Ratio | 3.24 |
Interest Coverage | — |
Quick Ratio
PIRS
Profitability
|
Metric
|
PIRS
|
|---|---|
Return on Assets (Normalized) | −10.09% |
Return on Equity (Normalized) | −25.98% |
Return on Invested Capital (Normalized) | −23.86% |
Return on Assets
PIRS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dmffqqfwg | Rkjp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kbvjvzkw | Mdhgcl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dbqmhxcf | Gxlmfr | $99.5 Bil | |
MRNA
| Moderna Inc | Glxtrfvn | Knhhm | $38.8 Bil | |
ARGX
| argenx SE ADR | Xgsctpmk | Lqwh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hgklvvshf | Jmlc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jpnwqcnxg | Sssyt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lyjdxgb | Zjzbs | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hkjtlsvqt | Lyygr | $12.5 Bil | |
INCY
| Incyte Corp | Ptdwbnw | Jqbfqy | $11.6 Bil |